Blood filter face-off: which removes dangerous antibodies faster?
NCT ID NCT03635385
First seen Feb 04, 2026 · Last updated Jun 23, 2026 · Updated 24 times
Summary
This study compared two blood-filtering techniques—plasma exchange and immunoadsorption—in 40 patients with severe kidney failure caused by ANCA vasculitis or anti-GBM disease. Both methods aim to rapidly remove harmful antibodies while waiting for immune-suppressing drugs to take effect. The goal was to see which technique clears antibodies faster, but the study was small and did not measure long-term outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GOODPASTURE SYNDROME are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Assisatance Publique Hôpitaux de Marseille
Marseille, 13354, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If one method proves faster at removing harmful antibodies, it could guide doctors to choose the better technique for severe kidney or lung involvement.
What could go wrong
This is a small pilot study (40 people) that only measures antibody removal speed, not long-term patient outcomes. It cannot prove which method is safer or more effective overall.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.